DEC 0 2 2003 CE

App. No.: 10/615,158

Inventor: Jeffery P. Gilbard et al.

Docket No.: AVR-005

Title: EPA AND DHA ENRICHED OMEGA-3 SUPPLEMENT FOR THE TREATMENT OF DRY EYE MEIBOMIANITIS AND

XEROSTOMIA

Fig. 1 DHA

DHA Biosynthesis (N-3 Pathway)

1/2

A-Linolenic Acid [18:3n-3]

[9, 12, 15]

delta 6 desaturation

Octadecatetraenoic Acid [18:4n-3]

[6, 9, 12, 15]

elongation

Eicosatetraenoic Acid [20:4n-3]

[8, 11, 14, 17]

delta 5 desaturation

Eicosapentaenoic Acid (EPA) [20:5n-3]

[5, 8, 11, 14, 17]

elongation

Docosapentaenoic Acid [22:5n-3]

[7, 10, 13, 16, 19]

elongation

Tetracosapentaenoic Acid [24:5n-3]

[9, 12, 15, 18, 21]

delta 6 desaturation

Tetracosahexaenoic Acid [24:6n-3]

[6, 9, 12, 15, 18, 21]

beta-oxidation

Docosahexaenoic Acid (DHA) [22:6n-3]

[4, 7, 10, 13, 16, 19]



XEROSTOMIA

2/2

Fig. 2 AA Biosynthesis (N-6 Pathway) Linoleic Acid [18:2n-6] [9, 12,] delta 6 desaturation Gamma-Linolenic Acid [18:3n-6] [6, 9, 12,]elongation Dihomo-Gamma-Linolenic Acid [20:3n-6] [8, 11, 14,]delta 5 desaturation Arachidonic Acid (AA) [20:4n-6] [5, 8, 11, 14,] elongation Docosatetraenoic Acid [22:4n-6] [7, 10, 13, 16,] delta 4 desaturation Docosapentaenoic Acid [22:5n-6]

[4, 7, 10, 16]